Tagged with EALTH

IMS Health Hungary IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from the other markets in the region? I believe none of the countries of the region is having a good time…

National Health Insurance House of Romania (CNAS) If we first take a look at the healthcare system in Romania, it is clear that finding adequate funding has been a key challenge for many years. With 3.6% of GDP being spent on healthcare, Romania equals levels of countries such as Burundi and Bangladesh. In your view, what were…

Bayer Healthcare Pharmaceuticals Russia You were a Russian manager from 1996-2004, departed to Germany for some time, and recently made your way back to Russia in 2010. How has Russian healthcare and industry changed, and what do you find most striking? The biggest difference is the fact that the government is much more involved…

Ministry of Health Voivodeships, Polish expenditure on health care system per one resident is still below the European average. In regards to the issue concerning the „expenditure on health care system”, I would like to inform you that the financial plan of the National Health Fund for 2011 provides that costs of health…

IMS Health Netherlands IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market? There are quite a few particularities. When we discuss the value of the pharmaceutical market in the Netherlands for example,…

Atlantic Healthcare Ltd A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status was granted in Europe. Many companies in the UK have named market access as a key challenge—but is that an…

Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…

IMS Health Malaysia You spent most of your career in the pharmaceutical industry with Bristol Meyers Squibb and earlier on for NV Organon which you joined in 1998. In 2007 you left to join the world of consultancy, how useful was this insider knowledge to your work and what is it like now…

National Institute for Health and Clinical Excellence (NICE) Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed out that NICE is admired globally for its evidence-based guidelines and the economic rigour of its Health Technology Assessments (HTAs).…

Office for the Strategic Coordination of Health Research (OSCHR) It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some examples of the new way forward. According to you, what are the factors that drove Government to pursue such drastic…

Ministry of Health (MOH) of Malaysia Would you begin by giving our readers a brief overview of the recent changes in the Ministry of Health’s focus? After Prime Minister Najib changed Malaysia’s economic policy from the ‘New Economic Policy’ to the ‘Economic Transformation Programme’ there has been a paradigm shift in the ministry’s focus. The government…

Taiwan Department of Health Paul Krugman, who won the 2006 Nobel Prize in economics, said that the Taiwanese health care system is the best in the world. Despite this, you are now drafting a second generation of legislation, so what are the issues that need to be addressed in this legislation? In any program…